Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Transcriptional and epigenetic regulation of ferroptosis in cancer drug resistance: Mechanisms and targeted therapeutic opportunities.

Created on 12 Sep 2026

Authors

Zenan Xu, Manxuan Zhang, Muhammad Faseeh, Shourong Wu, Wenfang Li

Published in

Biochemical pharmacology. Pages 118466. Sep 11, 2026. Epub Sep 11, 2026.

Abstract

Ferroptosis, an iron-dependent form of regulated cell death driven by excessive lipid peroxidation, has emerged as a critical determinant of cancer drug resistance. While significant progress has been made in understanding the core biochemical pathways of ferroptosis, the transcriptional and epigenetic mechanisms governing ferroptosis sensitivity in drug-resistant cancer cells remain incompletely understood. This review provides a comprehensive analysis of the transcriptional regulatory networks (Nrf2, YY1, p53, HIF-1α) and epigenetic modifications (DNA methylation, histone modifications, non-coding RNAs, chromatin remodeling) that orchestrate ferroptosis programs in drug resistance. Critically, we propose that transcriptional-epigenetic crosstalk represents the core driver of ferroptosis plasticity, enabling cancer cells to dynamically adapt to therapeutic stress. We integrate our team's original findings on YY1/YY2 homeostatic regulation of ferroptosis in colorectal cancer drug resistance and discuss the dual role of ferroptosis-both lethal and sublethal-in shaping tumor evolution and therapeutic outcomes. Furthermore, we systematically analyze preclinical and clinical progress in targeting transcriptional and epigenetic regulators to sensitize drug-resistant cancers to ferroptosis, highlighting rational combination strategies and major clinical translation bottlenecks. Finally, we propose five concrete future research directions that will advance the development of ferroptosis-based precision cancer therapy. This review bridges mechanistic epigenetic biology with translational pharmacology, providing a valuable reference for overcoming cancer drug resistance.

PMID:
42727656
Bibliographic data and abstract were imported from PubMed on 12 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement